Hosted on MSN11m
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challengesAt the heart of Eli Lilly's recent success and future prospects lies its formidable GLP-1 portfolio, headlined by Mounjaro (tirzepatide) and Zepbound. These drugs have shown remarkable efficacy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback